Tilray Medical Launches Direct-to-Patient Cannabis in UK via Lyphe

Direct-to-Patient Model Bypasses Traditional Wholesale Chains

Tilray Medical now sells branded cannabis medicines directly to UK patients through Lyphe's clinic-and-dispensary network, eliminating intermediary distributors. The partnership with Lyphe Clinic and Lyphe Dispensary gives Tilray Medical a patient-facing retail footprint in England, Scotland, and Wales. Until this launch, Tilray Medical supplied UK pharmacies and clinics exclusively through wholesale channels. No direct patient relationship. No brand visibility at point of sale.

Lyphe operates 14 brick-and-mortar dispensaries and an online platform serving roughly 22,000 registered medical cannabis patients across the UK, according to the company's Q2 2026 investor update. The clinic arm prescribes; the dispensary arm fulfills. Tilray Medical's products now appear under the Tilray Medical brand in both channels.

UK Medical Cannabis Market Grew 140% Year-Over-Year in 2025

The UK medical cannabis market dispensed approximately 680 kilograms per month in Q4 2025, up from 280 kilograms per month in Q4 2024, according to data from the UK's Home Office. Patient registrations doubled from 11,000 in January 2025 to 22,000 by December 2025. The market remains prescription-only; recreational cannabis is illegal under the Misuse of Drugs Act 1971.

Tilray Medical's entry into direct sales positions the company to capture margin currently held by third-party distributors. Wholesale pricing in the UK typically runs £4.50 to £6.00 per gram for flower, while patient-direct pricing through Lyphe ranges from £6.50 to £9.00 per gram, according to Lyphe's public price list.

Tilray Medical Expands European Footprint Beyond Germany

Tilray Medical operates cultivation and distribution in Germany, Portugal, and Canada, with the UK representing the company's fourth active European market. Germany remains Tilray's largest European revenue source, generating €47 million in medical cannabis sales in fiscal 2025. The UK launch follows Tilray's acquisition of a 19.9% stake in Lyphe Group in March 2026 for £8.2 million, which gave Tilray board representation and preferred distribution terms.

The Lyphe partnership mirrors Tilray's strategy in Germany, where the company operates both wholesale and direct-to-pharmacy sales through its subsidiary CC Pharma. For full background on this story, see the CannIntel topic hub on UK Medical Cannabis Market.

What Happens Next in the UK Market

Tilray Medical plans to introduce 12 additional SKUs through Lyphe by Q4 2026, including oils, capsules, and vaporizer cartridges. The initial launch includes four flower SKUs and two oil formulations. Lyphe's dispensary network will expand to 18 locations by year-end, according to the company's August 2026 press release.

The UK government is reviewing medical cannabis pricing and reimbursement policy under a consultation period that closes September 30, 2026. If the National Health Service begins covering medical cannabis prescriptions, patient volume could triple by mid-2027, according to projections from the UK Cannabis Industry Council.